Baili Tianheng (688506.SH): GNC-077 monoclonal antibody injection for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notification.

15:34 22/09/2024

Baili Tianheng (688506.SH) announced that the company has recently received approval from the National Medical Products Administration (NMPA)...

Baoli Tianheng (688506.SH) announced that the company recently received the official approval letter for the clinical trial of the company's independently developed innovative biopharmaceutical GNC-077 from the National Medical Products Administration (NMPA). According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, the clinical trial application for GNC-077 multi-specific antibody injection, which was accepted on July 16, 2024, meets the relevant requirements for drug registration, and the company has been authorized to conduct clinical trials for late-stage solid tumors.

HK Stock Market Move | GIANT BIOGENE (02367) fell more than 6% in the afternoon. The promotion of new medical and beauty products from approval to market still requires a certain amount of preparation time.

DU DU Holdings (08250) sells a total of 272,500 shares of Bairong-W.

GAPACK (00468) The company's equity owners' share of profit for the first 9 months was 76.98 million yuan, a decrease of 59.13% compared to the same period last year.

DU DU Holdings (08250) sells a total of 272,500 shares of Bairong-W.

GAPACK (00468) The company's equity owners' share of profit for the first 9 months was 76.98 million yuan, a decrease of 59.13% compared to the same period last year.